Clinical trial
Real-world Evidence Study on the Early Use of Cemiplimab in the UK: REACT-CEMI (Real World Evidence of Advanced CSCC Treatment - With CEMIplimab)
NCT05493826 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-world Evidence Study on the Early Use of Cemiplimab in the UK: REACT-CEMI (Real World Evidence of Advanced CSCC Treatment - With CEMIplimab)
- Lead sponsor
- Sanofi
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 18, 2022
- Completion date
- November 1, 2022
- Enrollment
- 110 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.